Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated.
BIIB shares were trading flat immediately following the announcement. The stock has slipped 9% since the beginning of this year.
Biogen also lowered its guidance for the full year, hurt by multiple Tecfidera generic entrants in the US.
Prior performance
Most Popular
Lamb Weston (LW) Q2 2026 Earnings: Key financials and quarterly highlights
Lamb Weston Holdings, Inc. (NYSE: LW) reported its second quarter 2026 earnings results today. Net sales inched up 1% year-over-year to $1.62 billion. Net sales at constant currency remained flat.
Paychex reports higher Q2 FY26 revenue and earnings; EPS beats estimates
Paychex Inc. (NASDAQ: PAYX) on Friday reported stronger-than-expected adjusted earnings for the second quarter of fiscal 2026. Revenues grew 18% year-over-year. The Rochester-based human capital management solutions provider reported revenues
Key highlights from NIKE’s (NKE) Q2 2026 earnings results
NIKE, Inc. (NYSE: NKE) reported revenues of $12.4 billion for the second quarter of 2026, which were up 1% on a reported basis and flat on a currency-neutral basis compared
